Pfizer Inc. (PFE)

FairStock Score: 46/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach Pfizer as a Graham-style bargain hunter: price versus defensible value first, narrative second. The business is a large, scaled drug and vaccine maker with familiar brands and a broad portfolio; that scale and patent-protected products can be a moat, but patents expire and pipeline execution matters. The recent record is mixed. In fiscal Q2 2026, the quarter ended 2026-06-28, revenue was $15.0B, net income was -$248.0M, and diluted EPS was -$0.04. For fiscal 2025, year ended 2025-12-31, revenue was $62.6B, net income $7.8B, and diluted EPS $1.36, down from fiscal 2024 revenue $63.6B, net income $8.0B, and diluted EPS $1.41. FairStock's calculated ROE is 5.01% and ROCE 5.78%, which are modest for the risk. Balance sheet leverage is D/E 0.74, and Piotroski 4/9 and Altman 1.85 suggest only middling financial strength. Cash generation is a positive: trailing FCF is $11.0B, a 6.5% FCF yield, alongside a 6.22% dividend yield, though I would want the payout covered by durable earnings. At the 2026-10-26 close of $29.79, FairStock's P/E is 39.20, P/B 1.99, and Graham Number $15.99, leaving a -87.80% margin of safety, meaning price is well above that conservative value estimate. FairStock scores it 48/100 and classifies it as SLOW GROWER — Shrinking: profit -3.2% a year over five years, revenue 8.5%. I see a high-yield, cash-generative but currently low-return company whose price demands recovery.

In plain English: Pfizer makes medicines and vaccines and sells them around the world. Revenue is large, but profit has been weak, including a loss in the latest reported quarter. Compared with its recent profits and assets, the shares look expensive, though the dividend yield is high.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-26 close · note generated 2026-10-28 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-28) · fiscal Q1 2026 10-Q (period ended 2026-03-29) · fiscal Q3 2025 10-Q (period ended 2025-09-28) · fiscal Q2 2025 10-Q (period ended 2025-06-29) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer